• Collect data from a sample of health care facilities in the United
States to permit valid estimation of the magnitude of adverse events among patients and health care personnel.
States to permit valid estimation of the adherence to practices known to be associated with prevention of these adverse events.
• Analyze and report collected data to permit recognition of trends.
• Provide facilities with risk-adjusted metrics that can be used for inter-facility comparisons and local quality improvement activities.
• Assist facilities in developing surveillance and analysis methods that permit timely recognition of patient and health care worker safety problems and prompt intervention with appropriate measures.
• Conduct collaborative research studies with NHSN mem ber facilities (eg, describe the epidemiology of emerging health care-associated infection [HAI] and pathogens, assess the importance of potential risk factors, further characterize HAI pathogens and their mechanisms of resistance, and evaluate alternative surveillance and prevention strategies).
• Comply with legal requirements e including but not limited to state or federal laws, regulations, or other requirements e for mandatory reporting of health care facility-specific adverse event, prevention practice adherence, and other public health data.
• Enable health care facilities to report HAI and prevention practice adherence data via NHSN to the U.S. Centers for Medicare and Medicaid Services (CMS) in fulfillment of CMS's quality measurement reporting requirements for those data.
• Provide state departments of health with information that identifies the health care facilities in their state that participate in NHSN.
• Provide to state agencies, at their request, facility-specific, NHSN patient safety component and health care personnel safety component adverse event and prevention practice adherence data for surveillance, prevention, or mandatory public reporting.
Patient-and facility-specific data reported to CDC are kept confidential in accordance with sections 304, 306, and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).
METHODS

Data collection methods
For reporting to the DA Module, health care facility personnel responsible for infection prevention and patient safety may choose, with consideration of state mandates, federal reporting programs, and prevention initiatives, to collect data on central line-associated bloodstream infections (CLABSI), ventilator-associated pneumonias (VAP), or urinary catheter-associated urinary tract infections (CAUTI) that occur in patients staying in a patient care location such as a critical or intensive care unit (ICU), specialty care area, or inpatient ward. In NHSN, locations are further stratified according to patient population: adults, children, or neonates (in tables, pediatric and neonatal locations are so noted). In neonatal intensive care unit (NICU) locations (level III or level II/III), infection pre ventionists (IPs) collect data on CLABSI or VAP that occur in patients in each of five birth-weight categories (�750 g, 751-1,000 g, 1,001 1,500 g, 1,501 -2,500 g, and >2,500 g); data on CAUTI are not collected as part of the NHSN protocols in any NICU location. Cor responding location-specific denominator data consisting of patient-days and specific device-days are also collected by IPs or other trained personnel.
In non-NICU locations, the device-days consist of the total number of central line-days, urinary catheter-days, or ventilatordays. For specialty care areas and oncology units, such as hema tology/oncology and hematopoietic stem cell transplant locations, central line-days are split into those with only a permanent central line vs those with temporary central lines (with or without a permanent central line). In NICU locations, the device-days consist of the total number of central line-days (inclusive of umbilical catheters), or ventilator-days for each birth-weight category.
Data analysis methods
Compared to the previous report, five new locations d gastrointestinal ward, pediatric orthopedic ward, inpatient hospice ward, solid tumor ward, and pediatric inpatient rehabilitation facility e had sufficient data to be included in this report. 1 Locations were further stratified by facility type, unit bed size and/or major teaching status to determine if pooled mean rates, medians, and empirical distributions significantly dif fered between two groups for all DA infections; if differences were present, the strata were retained for reporting. Com parisons of pooled mean rates were performed using Poisson regression. These comparisons could be influenced by potential outlier rates from locations with disproportionately large de nominators. Therefore, greater weight was given to the results of nonparametric tests comparing the medians for location shift and empirical distributions for assessing differences across the range of reported rates. These nonparametric comparisons by definition require no validity assumptions and provide test results that are not subject to the potential weighting influence of high or low rates with large denominators. Comparisons of the pooled mean, median and percentile distribution were made if there were at least 50 locations contributing to one or more strata and at least � 20 locations contributing to the percentile distribution in both strata. Existing strata were retained for adult combined medical/ surgical ICUs, medical ICUs, and surgical ICUs. The data for adult combined medical/surgical ICUs were split by medical school affiliation and unit bedsize, resulting in three groups: "major teaching," "all others" with unit bedsize 15 beds, and "all others" with unit bedsize >15. The data for adult medical ICUs and adult surgical ICUs were split into two groups by teaching status. Hospitals self-identified their teaching hospital status through the annual NHSN facility survey. A major teaching hospital was defined as a hospital that has a program for medical students and post-graduate medical training. Locations within critical access hospitals (CAHs) were compared to their counterparts in all other acute care hospitals. The statistical evidence indicated that there was a significant difference in these strata and therefore, data from CAHs have been reported separate from all other location types. Adult hematology/oncology locations were also evaluated to assess importance of status as an oncology hospital, but differ ences were not significant and no new strata for this population were retained.
Device utilization (DU) was calculated as a ratio of device-days to patient-days for each location type. As such, the DU of a loca tion is one measure of the use of invasive devices and constitutes an extrinsic risk factor for health care-associated infection.
10 DU may also serve as a marker for severity of illness of patients (ie more severely ill patients are more likely to require an invasive device) which is another reflection of the intrinsic susceptibility to infection. Data from at least 5 different reporting units of a given location type were used to determine pooled mean DA infection rates and DU ratios. Percentile distributions were determined if there were data from at least 20 different locations, excluding rates or DU ratios for locations that did not report at least 50 device-days or patient-days. Because of these requirements, the number of locations contributing data may vary among the tables.
RESULTS
In 2012, 4,444 enrolled facilities reported at least one month of DA denominator data for some patient cohorts under surveillance. These 4,444 facilities were located in 53 states, territories, and the District of Columbia and were predominantly general acute care hospitals (Table 1) ; 27% of all facilities that reported data were smaller organizations of 50 beds or less, comprised mostly of acute care hospitals that were not identified as critical access. Among LTACHs and IRFs, 59% and 86%, respectively, were categorized as physically free-standing from a hospital setting (Table 2) . Where data volume was sufficient for this report, we tabulated DA infec tion rates and DU ratios for January through December 2012 (Tables 3-10) . Data on the specific criteria used to report DA infections are provided in Tables 11-18.  Tables 3-6 update and augment previously published DA rates and DU ratios by type of non-NICU locations. 1 Based on results of statistical comparisons, data from CAHs are reported separately from all other acute care hospitals. These data are further stratified into combined critical care units and combined non-critical care units. Tables 7-10 update and augment the previously published DA rates and DU ratios by birth-weight category for NICU locations. 1 Beginning in January 2012, CLABSI data in NICU locations were no longer collected according to central line type (ie, central line and umbilical catheter); therefore, CLABSI rates and DU ratios for NICUs are not stratified by line type in this report. Tables 11-18 provide data on select attributes of the DA infec tions for each location. For example, Tables 11, 12, 15 and 16 show the frequency and percent distribution of the specific sites of CLABSI and the criteria used for identifying these infections. Note that for these tables, criteria 2 and 3, which involve common commensals only, have been combined.
DISCUSSION
This report summarizes the HAI data reported to the DA module of NHSN during 2012. Compared to the health care facility types for which HAI data were summarized in the last published report, in this report there is a slight increase in smaller hospitals, IRFs, and LTACHs. 1 Based on the number of facilities reporting, overall contribution from all facility types to the device-associated module increased by 15% from the last report. 1 This increase in reporting is largely attributable to health care facilities' participation in CMS's Quality Reporting Programs which require participants to use NHSN as the tool to report CLABSI data from all acute care hospital adult, pediatric, and neonatal ICUs (effective as of January 2011) and all LTACH loca tions, as well as CAUTI data from all acute care hospital adult and pediatric ICUs, and all LTACH and IRF locations (effective as of January 2012). 8, 9 While this growth impacted the volume of reporting in these designated settings, there is also an indication of increased participation in ward locations for CLABSI and CAUTI surveillance. Extensive analyses of the impact of facility type and medical school affiliation on all DA infection rates were performed for select locations. Medical school affiliation continues to be a significant factor for all three DA infection rates and/or percentile distributions in medical ICUs and surgical ICUs. All DA infection rate pooled means in this report continue to be higher in those locations stratified as major teaching compared to their non-major teaching counterparts. This suggests room for targeted prevention efforts in these settings that care for higher complexity patients. Addi tionally, medical school affiliation and bed size both continue to be significant factors in DA infection rates for medical/surgical ICUs. Note that while the CLABSI rates between unit bedsize strata in medical/surgical "all other" ICUs are equal (Table 3) , the The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, :50 device days for rate distributions, :50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. percentile distributions were shown to be significantly different as a result of nonparametric statistical tests. Therefore, this stratification by unit bedsize in "all other" medical/surgical ICUs was retained. Adult hematology/oncology locations were not further stratified by hospital type (ie, oncology hospital vs all other acute care hospitals) as the results of the statistical tests indicated that the differences in the strata were not statistically significant. In 2013, oncology and general acute care hospitals were provided with fourteen oncology-specific CDC locations with which to identify for device-associated infection surveil lance. As the volume of these data become sufficient, future analyses will continue to assess any potential differences in this specialized population.
In 2012, facilities participating in NHSN were able to designate themselves as CAHs. This information allowed for the compar ison of DA rates and DU ratios in these hospitals to all other hospitals. The results of the statistical tests indicated that DA rates and DU ratios in CAHs are significantly different from all other hospitals and therefore, CAHs are now able to compare themselves to pooled means generated from like-hospitals. This allows for more targeted prevention efforts in this unique setting. In producing this report, there were several areas identified for Tables 11-18 were included to aid the reader in interpreting the which prevention activities and further investigation may be DA infection rates data. One important use of data in these tables is needed, both at the national and local levels. For example, the to better understand the distribution of DA infections by type of CLABSI pooled mean rate for LTACH critical care units is higher than reporting criterion nationally. For example, nearly 85% of the most other critical care unit types (Table 3) . Similarly, the CAUTI CLABSIs from adult and pediatric ICUs and inpatient wards were pooled mean rate for LTACH wards is higher than CAUTI pooled identified using criterion (1) which attributes the CLABSI to mean rates in the majority of other ward-level locations (Table 5) . a recognized pathogen; however, for NICUs, only 70% used this Further, when compared to the previous report, CAUTI rates have criterion, resulting in a greater percentage of CLABSIs in this popincreased in every critical care unit type, with the exception of ulation that were identified with common commensals. Similarly, "Surgical critical care e all others" (Table 5) . 1 Additional key findthe specific type of ventilator-associated pneumonia (VAP) most ings from this report can be found in Figure 1 .
frequently reported, regardless of location, was the clinical criterion The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, :50 device days for rate distributions, :50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. yy Number of urinary catheter -days x 1; 000. Number of patient -days The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, :50 device days for rate distributions, :50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. Number of central line -days z . Number of VAP * x 1; 000. Number of ventilator -days y The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, :50 device days for rate distributions, :50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. Number of ventilator -days z . Number of VAP * x 1; 000. Number of ventilator -days y The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, :50 device days for rate distributions, :50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. Number of ventilator -days z . Number of patient -days (continued on next page) of the data increases. NHSN will continue to assess how chan ging facility composition and changes in the proportion of (PNU1) which relies on the somewhat subjective interpretations of data contributed by facility types impact the rates and their clinical findings. distributions so that the best possible risk-adjusted comparative As diverse types of facilities continue to participate in NHSN, data may be provided in future reports. either voluntarily or by mandate, the need for careful scrutiny To improve the reliability of data reported to NHSN, several protocol changes were introduced in January 2013. The majority of these changes were with respect to timing and implementation of two-day rules to clarify infections that are health careassociated, association of device use to HAI, and attribution of HAI to an inpatient location after transfer or to a hospital after discharge. In addition, NHSN added criteria for mucosal barrier injury laboratory-confirmed bloodstream infections, which have not been removed or accounted for separately in this report. Finally, the VAP definition no longer applies to adult patients (ie, : 18 years of age) and this definition has been replaced by ventilator-associated events (VAEs). 11 We will carefully assess the potential impact of these changes on HAI incidence as these data are reported.
Number of patient -days
For those who do not report to NHSN but would like to use these data for comparison, the information must first be collected from your hospital in accordance with the methods described for NHSN. [5] [6] [7] Refer to Appendices A and B for further instructions. Appendix A discusses the calculation of infection rates and DU ratios for the DA Module. Appendix B gives a step-by-step method for interpretation of percentiles of infec tion rates or DU ratios. Although a high rate or ratio (>90th percentile) does not necessarily define a problem, it does suggest an area for further investigation. Similarly, a low rate or ratio (<10th percentile) may be the result of inadequate infection detection.
Facilities should use the data in this report and their own data to guide local prevention strategies and other quality improvement efforts to reduce the occurrence of infections as much as possible. The data presented in this report can be used to prioritize prevention efforts in those patient care areas that are shown to have the highest incidence of DA infections and/or high device utilization. Facilities may also wish to set targets based on the percentile distributions provided in this report in an effort to strive for lower rates and greater preven tion success.
The authors are indebted to the NHSN participants for their ongoing efforts to monitor infections and improve patient safety. We also gratefully acknowledge our colleagues in the Division of Healthcare Quality Promotion who tirelessly sup port this unique public health network, especially our collea gues in: Calculation of device utilization (DU) ratio
Steps 1, 2, 4: Same as device-associated infection rates plus determine the number of patient-days which is used as the denominator of the DU ratio. Patient-days are the total number of days that patients are in the location during the selected time period.
Example: Ten patients were in the unit on the first day of the month; 12 on day 2; 11 on day 3; 13 on day 4; 10 on day 5; 6 on day 6; and 10 on day 7; and so on. If we counted the patients in the unit from days 1 through 7, we would add 10 þ 12 þ 11 þ 13 þ 10 þ 6 þ 10 for a total of 72 patient-days for the first week of the month. If we continued for the entire month, the number of patient-days for the month is simply the sum of the daily counts.
Step 5: Calculate the DU ratio with the following formula:
Number of device-days DU Ratio ¼ Number of patient-days With the number of device-days and patient-days from the examples above, DU ¼ 28/72 ¼ 0.39 or 39% of patient-days were also central line-days for the first week of the month.
Step 6: Examine the size of the denominator for your hospital's rate or ratio. Rates or ratios may not be good estimates of the "true" rate or ratio for your hospital if the denominator is small, ie, <50 device-days or patient-days.
Step 7: Compare your hospital's location-specific rates or ratios with those found in the tables of this report. Refer to Appendix B for interpretation of the percentiles of the rates/ratios.
APPENDIX B. INTERPRETATION OF PERCENTILES OF INFECTION RATES OR DEVICE UTILIZATION RATIOS
Step 1: Evaluate the rate (ratio) you have calculated for your hospital and confirm that the variables in the rate (both numerator and denominator) are identical to the rates (ratios) in the table.
Number of central line-days
Step 2: Examine the percentiles in each of the tables and look for the 50th percentile (or median). At the 50th percentile, 50% of the hospitals have lower rates (ratios) than the median and 50% have higher rates (ratios).
Step 3: Determine if your hospital's rate (ratio) is above or below this median.
Determining whether your hospital's rate or ratio is a HIGH outlier
Step 4: If it is above the median, determine whether the rate (ratio) is above the 75th percentile. At the 75th percentile, 75% of the hospitals had lower rates (ratios) and 25% of the hospital had higher rates (ratios).
Step 5: If the rate (ratio) is above the 75th percentile, determine whether it is above the 90th percentile. If it is, then the rate (ratio) is an outlier which may indicate a problem.
Determining whether your hospital's rate or ratio is a LOW outlier
Step 6: If it is below the median, determine whether the rate (ratio) is below the 25th percentile. At the 25th percentile, 25% of the hospitals had lower rates (ratios) and 75% of the hospitals had higher rates (ratios).
Step 7: If the rate (ratio) is below the 25th percentile, determine whether it is below the 10th percentile. If the rate is, then it is a low outlier which may be due to underreporting of infections. If the ratio is below the 10th percentile, it is a low outlier and may be due to infrequent and/or short duration of device use.
Note: Device-associated infection rates and device utilization ratios should be examined together so that preventive measures may be appropriately targeted. For example, you find that the ventilatorassociated pneumonia rate for a certain type of ICU is consistently above the 90th percentile and the ventilator utilization ratio is routinely between the 75th and 90th percentile. Since the ventilator is a significant risk factor for pneumonia, you may want to limit the duration of ventilation whenever possible (ie, decrease unnecessary use) while at the same time optimize infection prevention strategies in patients for which ventilator use is required.
